Why Aurinia Pharmaceuticals Inc.’s (AUPH) Stock Is Down 6.37%
As of Friday, August 21, Aurinia Pharmaceuticals Inc.’s AUPH share price has dipped by 6.37%, which has investors questioning if this is right time to buy.Michael Rose
Stock Evaluator: Aurinia Pharmaceuticals Inc. (AUPH)
Aurinia Pharmaceuticals Inc. AUPH
$16.65
-0.62
-3.59%
August 21, 2026 4:00:00 PM
EST
Volume: 1,248,760
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Commentary & Analysis
Which Is a Better Investment, Aurinia Pharmaceuticals Inc. or Xencor, Inc. Stock?
Learn more about whether Aurinia Pharmaceuticals Inc. or Xencor, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Michael Rose
4 Undervalued Biotechnology Stocks for Thursday, August 13
Discover the top 4 undervalued Biotechnology stocks for Thursday, August 13 based on AAII’s Stock Grades.Rosalio Madrigal
Which Is a Better Investment, Aurinia Pharmaceuticals Inc. or CareDx, Inc. Stock?
Learn more about whether Aurinia Pharmaceuticals Inc. or CareDx, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
Which Is a Better Investment, Aurinia Pharmaceuticals Inc. or Ionis Pharmaceuticals, Inc. Stock?
Learn more about whether Aurinia Pharmaceuticals Inc. or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
Financial Summary
| Share Statistics | AUPH | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,215.3 | $292.6 | 55% |
|
| Shares Out (Mil) | 133.5 | 54.4 | 68% |
|
| Institutional Ownership | 96.5% | 93.2% | 70% |
|
| Float (Mil) | 128.8 | 40.2 | 66% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 1,231 | 544 | 74% |
|
| Price Change (52-week) |
38.6% | 59.7% | 73% |
|
| Growth | AUPH | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 41.4% | 13.6% | 94% |
|
| Net Income (5yr) | 36.8% | (10.1%) | 89% |
|
| EPS (5yr) | 34.4% | 16.0% | 85 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 41.0% | (15.6%) | 91% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 6 | |
| Current EPS | $0.220 | $0.944 | $1.067 | |
| Month Ago EPS | $0.238 | $0.950 | $1.107 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | $0.243 | $0.960 | $1.118 | |
| Year/Year Chg | (21.4%) | (54.4%) | (43.1%) | |
| Financials | AUPH | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $312 | $37 | 36% |
|
| Net Income (TTM) (Mil) | $314 | ($43) | 73% |
|
| EPS (TTM) | $2.388 | ($1.400) | 74% |
|
| Operating Cash Flow (TTM) (Mil) | $175 | ($31) | 57% |
|
| Net Cash Flow (TTM) (Mil) | $127 | $2 | 79% |
|
| Long-Term Debt (Q1) (Mil) | $46 | $4 | 38% |
|
| Enterprise Value (Q1) (Mil) | na | $164 | na |
|
| Valuation | AUPH | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.60 | 2.83 | 69% |
|
| P/E | 7.2 | 19.6 | 8% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.2 | 1.0 | 9% |
|
| Ratios | AUPH | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 77.9% | 64.2% | 87% |
|
| Net Margin | 100.8% | (75.9%) | 99% |
|
| ROA | 48.5% | (47.5%) | 99% |
|
| ROE | 66.1% | (55.0%) | 94% |
|
| Liabilities to Assets | 22.4% | 29.6% | 15% |
|
| F-Score | 7 | 3 | 82% |
|
Passing Stock Screens
As of 8/21/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Fundamental Rule of Thumb Screen
Factors: Value
An old value screen combining the P/E ratio, dividend yield, and an adjusted return on equity that's still applicable in today's market.
| Performance Since Inception: | 6.6% |
| +/- S&P 500: | -0.9 |
FACTOR STRATEGY
Price-to-Sales Screen
Factors: Value, Growth
Research indicates that using price-to-sales ratios may lead to better investment results than price-to-book-value ratios or price-earnings ratios.
| Performance Since Inception: | 13.0% |
| +/- S&P 500: | +5.5 |
FACTOR STRATEGY
Return on Equity Screen
Factors: Quality, Growth
A screen that identifies stocks with above average earnings and sales growth that have consistently outperformed their peers measured by ROE.
| Performance Since Inception: | 13.1% |
| +/- S&P 500: | +5.6 |
